MedTrace Logo

Inflammatory Blood Markers in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy

NCT05468710 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2022-07-21

No results posted yet for this study

Summary

Breast cancer is the most threatening disease in women. Neoadjuvant chemotherapy is a commonly used for the treatment. Inflammation plays an important role in tumor proliferation, metastasis, and resistance to chemotherapy. Inflammatory blood markers (IBM) reflect the balance between host inflammatory and immune status. Different IBM have been reported as prognostic factors for survival and predictive factors for pathological complete response and toxicity. Our aim to evaluate these IBM in breast cancer patients receiving neoadjuvant chemotherapy.

Conditions

Sponsors & Collaborators

  • Ain Shams University

    lead OTHER

Principal Investigators

  • Nivine M Gado, phd · Ain Shams University

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-30
Primary Completion
2023-07-31
Completion
2023-12-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05468710 on ClinicalTrials.gov